The FDA outlined guidance for Atara’s resubmission of its biologics license application, boosting investor confidence in the therapy’s approval prospects.
Atara Biotherapeutics (ATRA) stock rose sharply after the FDA provided clear guidance for resubmitting its biologics license application for tabelecleucel. The agency’s feedback removes a key regulatory hurdle for the therapy, which targets Epstein-Barr virus-associated diseases.
Shares had slumped earlier this year following a complete response letter from the FDA in December. Analysts had cited uncertainty around the resubmission process as a major overhang for the stock. The latest guidance offers a defined pathway for addressing the agency’s concerns.
The market reaction was immediate, with ATRA shares climbing over 30% in premarket trading. The company plans to submit additional data to support the application in the coming months.